Replies to post #1636 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

I don't know what the Wall Street consensus EPS was. (I rarely pay attention to such numbers.) However, ENTA's quarterly revenue of $44M was pretty easy to peg given ABBV's announced sales figure for Mavyret. ENTA's R&D expenses and GAAP tax rate were a little better than some people probably expected, which boosted the EPS.